Brokerages predict that Kadmon Co. (NYSE:KDMN) will post sales of $2.67 million for the current quarter, Zacks reports. Three analysts have provided estimates for Kadmon’s earnings, with the highest sales estimate coming in at $3.46 million and the lowest estimate coming in at $1.45 million. Kadmon posted sales of $5.57 million during the same quarter last year, which suggests a negative year over year growth rate of 52.1%. The business is scheduled to issue its next quarterly earnings results on Monday, May 21st.
According to Zacks, analysts expect that Kadmon will report full-year sales of $9.94 million for the current year, with estimates ranging from $5.50 million to $16.70 million. For the next year, analysts forecast that the firm will post sales of $47.92 million per share, with estimates ranging from $5.60 million to $117.36 million. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Kadmon.
Kadmon (NYSE:KDMN) last posted its quarterly earnings results on Tuesday, March 6th. The company reported ($0.24) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.36) by $0.12. The business had revenue of $1.50 million during the quarter, compared to the consensus estimate of $3.07 million. During the same quarter in the previous year, the company earned ($0.50) earnings per share. The company’s revenue for the quarter was down 65.1% compared to the same quarter last year.
KDMN has been the subject of several recent analyst reports. Zacks Investment Research upgraded Kadmon from a “hold” rating to a “buy” rating and set a $4.25 price target for the company in a research note on Friday, January 12th. Jefferies Group upped their price target on Kadmon to $16.00 and gave the stock a “buy” rating in a research note on Tuesday, February 13th. Piper Jaffray restated a “positive” rating and issued a $9.00 price target (up from $7.00) on shares of Kadmon in a research note on Tuesday, February 13th. Finally, HC Wainwright restated a “buy” rating and issued a $25.00 price target on shares of Kadmon in a research note on Friday, March 9th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $11.45.
KDMN stock traded down $0.08 during midday trading on Monday, hitting $4.25. The company’s stock had a trading volume of 178,597 shares, compared to its average volume of 907,608. Kadmon has a 12 month low of $2.05 and a 12 month high of $5.86. The company has a market capitalization of $340.52, a price-to-earnings ratio of -2.99 and a beta of 3.90.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Sawtooth Solutions LLC bought a new position in shares of Kadmon during the 4th quarter valued at approximately $799,000. Goldentree Asset Management LP boosted its position in shares of Kadmon by 673.6% during the 4th quarter. Goldentree Asset Management LP now owns 1,611,730 shares of the company’s stock valued at $5,834,000 after acquiring an additional 1,403,397 shares during the last quarter. BlueCrest Capital Management Ltd bought a new position in shares of Kadmon during the 4th quarter valued at approximately $241,000. Geode Capital Management LLC boosted its position in shares of Kadmon by 172.4% during the 4th quarter. Geode Capital Management LLC now owns 463,844 shares of the company’s stock valued at $1,679,000 after acquiring an additional 293,569 shares during the last quarter. Finally, Spark Investment Management LLC bought a new position in shares of Kadmon during the 4th quarter valued at approximately $868,000. Hedge funds and other institutional investors own 61.71% of the company’s stock.
Kadmon Company Profile
Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics within autoimmune and fibrotic, oncology, and genetic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including those indicated for the management of rare diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.